ALK and non-small cell lung carcinoma: Huang et al., described the safety and efficacy of crizotinib combined with bevacizumab, a monoclonal antibody targeting VEGF, in 14 patients with NSCLC, among whom ALK rearrangements were detected in 12 patients.